3d Bioprinting Market Analysis

The 3D bioprinting is the usage of the 3D printing such methods to integrate the cells, development factors and the biomaterials to fabricate the bioclinical parts generally with the focus of imitating the natural cells characteristics. Usually, 3D bioprinting can use a layer by layer procedure to deposit the substances called as bioinks to make the tissue such as structures that are later utilized in several clinical and tissue fields.

Statistics:

The 3D bioprinting market was valued at US$ 875.33 Mn in 2021 and is forecast to reach a value of US$ 4,815.02 Mn by 2030 at a CAGR of 21% between 2022 and 2030.

Figure 1: Global 3D Bioprinting Market Value (US$ Mn) Analysis and Forecast, 2017 - 2030

North America held a dominant position in the Global 3D Bioprinting Market Share in 2021

Statistics:

North America held dominant position in the Global 3D Bioprinting Market in 2021, accounting for 40% share in terms of volume.

Figure 2: Global 3D Bioprinting Market Share (%), By Region, 2021

Key Developments:

In January 2021, the 3D systems adopted the additive works to increase the AM software assortment and the creation capacity, which would increased with the additive production over the industrial and the hospital markets. 3D systems adopted Allevi to increase the application chances for the AM in the clinical and the huge reliability applications.

In 3D systems and CollPlant biotechnologies declared a joint advancement and the boosting creation in the biomedical industry. This deal would be aiming on the growth of the regenerative drugs and medications with the assistance of the 3D bioprinting.

3D Bioprinting Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2021:	US$ 875.33 Mn
Historical Data for:	2017 to 2030	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	21%	2030 Value Projection:	US$ 4,815.02 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Technology: Syringe/extrusion Bioprinting, Inkjet Bioprinting, Magnetic Levitation Bioprinting, Laser-assisted Bioprinting, Other Technologies By Component: 3D Bioprinters, Biomaterials, Scaffolds By Application: Drug Testing and Development, Regenerative Medicine, Food Testing, Research, Other Applications
Companies covered:	Major companies involved in the global 3D printing market are 3D Systems Corporation, Cyfuse Biomedical KK, GeSIM GmbH, 3D Bioprinting Solutions,  Aspect Biosystems Ltd., Organovo Holdings Inc., ARCAM AB (GE Company), Cellink AB, RegenHU SA, REGEMAT 3D, EnvisionTEC GmbH and Stratasys Ltd
Growth Drivers:	Rising geriatric population Rising investment in R&D
Restraints & Challenges:	Operational Challenges Limitation of the biomaterials

Market Drivers:

Driver 1:

The elderly populace is poised as one of the main notable social changes of the twenty first century and the worldwide population of the age above 60 years is rising rapidly than all the younger age groups which is anticipated to augment the growth of the global 3D bioprinting market.

Driver 2:

The number of elderly population above 60 years is anticipated to be doubled by the year 2025, and it is rising rapidly than the age group comprising of the youth globally. This trend has a rising need for the caregivers offering 24 hours care not only at the healthcare centers or the nursing homes but also the apartments and the private homes.

Market Restraint:

Restraint 1:

The organ printing is a computer aided procedure in which the cells or the tissues and the cell laden biomaterials are fit as per a carbon print design and serve as the building block that are later gathered into the 3D constructs and the matured functional organ creation and the formation is anticipated to hinder the growth of the global 3D bioprinting market.

Restraint 2:

An automated reach provides a way to the scalable and the reproducible mass production of the engineered organs and parts in which the multiple cells form can be placed to mimic the organic counterparts. To effectively use the organ printing at the medical level, rigid automated protocols and the processes should be established.

Market Opportunities:

Opportunity 1:

The 3D printing of the existing appliances has made a notable effect on the hospital segment due to the effective research and development of the universities and the critical organizations. Apart from the production fabric tissues, the 3D bioprinting has also helped the hospital segment with the personalization and the customization of the clinical goods and medicines.

Opportunity 2:

During the predicted duration, the 3D bioprinting is anticipated to revolutionize or change the hospital with a creative or the innovative wave of the developments in the operations and the therapies. It is regarded as the secured method to fabricate human cells with the decreased price and threat.

Market Key Takeaways/Trends:

Trend 1:

Currently, the Biolife 4D gained a notable milestone by the printing of 3D heart, which will let the biotech firm at  a roadmap to gain its ultimate goal of the bioprinting a full scale human cardiac viable for the transplantation the replacement. Likewise activities and the developments by the industries in the market are anticipated boost the adoption of the 3D bioprinting market in the medical sector during the predicted duration.

Trend 2:

The rising need for the organ transplantation due to the rising cases of the vital organ failure is anticipated to help the companies or the industries to spend and then conduct the research and development activities on the similar thing. Furthermore, the pharma companies are making the utilization of 3D bioprinter tissue.

Competitive Landscape:

Major companies involved in the global 3D printing market are 3D Systems Corporation, Cyfuse Biomedical KK, GeSIM GmbH, 3D Bioprinting Solutions,  Aspect Biosystems Ltd., Organovo Holdings Inc., ARCAM AB (GE Company), Cellink AB, RegenHU SA, REGEMAT 3D, EnvisionTEC GmbH and Stratasys Ltd